XOMA Stock Forecast, Price & News

-0.73 (-3.06 %)
(As of 09/21/2021 01:32 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume293 shs
Average Volume38,155 shs
Market Capitalization$261.85 million
P/E Ratio110.24
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

XOMA logo

About XOMA

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.00 out of 5 stars

Medical Sector

567th out of 1,352 stocks

Pharmaceutical Preparations Industry

275th out of 665 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

XOMA (NASDAQ:XOMA) Frequently Asked Questions

Is XOMA a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XOMA stock.
View analyst ratings for XOMA
or view top-rated stocks.

What stocks does MarketBeat like better than XOMA?

Wall Street analysts have given XOMA a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but XOMA wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is XOMA's next earnings date?

XOMA is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for XOMA

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) released its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.35) by $0.04. The biotechnology company earned $0.90 million during the quarter, compared to analysts' expectations of $2.09 million. XOMA had a trailing twelve-month return on equity of 5.88% and a net margin of 16.11%.
View XOMA's earnings history

How has XOMA's stock been impacted by Coronavirus?

XOMA's stock was trading at $19.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XOMA shares have increased by 18.7% and is now trading at $23.15.
View which stocks have been most impacted by COVID-19

What price target have analysts set for XOMA?

3 brokerages have issued twelve-month target prices for XOMA's stock. Their forecasts range from $22.00 to $56.00. On average, they expect XOMA's share price to reach $44.67 in the next twelve months. This suggests a possible upside of 92.9% from the stock's current price.
View analysts' price targets for XOMA
or view top-rated stocks among Wall Street analysts.

Who are XOMA's key executives?

XOMA's management team includes the following people:
  • James R. Neal, Chief Executive Officer & Director
  • Thomas Burns, Chief Financial Officer & Senior VP-Finance

What is John Varian's approval rating as XOMA's CEO?

11 employees have rated XOMA CEO John Varian on John Varian has an approval rating of 73% among XOMA's employees.

Who are some of XOMA's key competitors?

What other stocks do shareholders of XOMA own?

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

Who are XOMA's major shareholders?

XOMA's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (6.45%), BlackRock Inc. (4.04%), Vanguard Group Inc. (3.46%), Opaleye Management Inc. (3.04%), Geode Capital Management LLC (1.24%) and State Street Corp (1.06%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, Matthew D Perry, Thomas M Burns and Value Fund L P Biotechnology.
View institutional ownership trends for XOMA

Which major investors are selling XOMA stock?

XOMA stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., BlackRock Inc., JPMorgan Chase & Co., Bank of America Corp DE, Price T Rowe Associates Inc. MD, California State Teachers Retirement System, and Deutsche Bank AG. Company insiders that have sold XOMA company stock in the last year include Bvf Partners L P/Il, James R Neal, and Thomas M Burns.
View insider buying and selling activity for XOMA
or view top insider-selling stocks.

Which major investors are buying XOMA stock?

XOMA stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Nuveen Asset Management LLC, Vanguard Group Inc., Morgan Stanley, and Morgan Stanley. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal, Matthew D Perry, and Value Fund L P Biotechnology.
View insider buying and selling activity for XOMA
or or view top insider-buying stocks.

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $23.15.

How much money does XOMA make?

XOMA has a market capitalization of $261.85 million and generates $29.39 million in revenue each year. The biotechnology company earns $13.30 million in net income (profit) each year or $0.78 on an earnings per share basis.

How many employees does XOMA have?

XOMA employs 10 workers across the globe.

When was XOMA founded?

XOMA was founded in 1981.

What is XOMA's official website?

The official website for XOMA is

Where are XOMA's headquarters?

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at (510) 204-7200 or via email at [email protected].

This page was last updated on 9/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.